Valsartan and Hydrochlorothiazide Dispersible Tablets
Belongs to Category:
The company has production licenses for tablets, capsules, granules, suppositories, powders, injections, oral solutions, dry suspensions, and eye drops.
Product Description
Approval Number:
H20090262
Indications:
Used to treat mild to moderate primary hypertension that cannot be adequately controlled with a single drug. This product is not suitable for the initial treatment of hypertension.
Administration：
Each tablet contains 80mg Valsartan and 12.5mg Hydrochlorothiazide. When blood pressure cannot be satisfactorily controlled with Valsartan monotherapy, or when blood pressure cannot be satisfactorily controlled with 25mg Hydrochlorothiazide once daily, or hypokalemia occurs, this product (containing 80mg Valsartan/12.5mg Hydrochlorothiazide) can be used, one tablet at a time, once daily. The maximum antihypertensive effect can be achieved within 2-4 weeks of medication.
Specifications:
80mg/12.5mg × 14 tablets
The company has production licenses for tablets, capsules, granules, suppositories, powders, injections, oral solutions, dry suspensions, and eye drops.
The main products cover cardiovascular diseases, diabetic complications, anti-tumor, calcium supplementation, digestive system, respiratory system, and orthopedics.
Related Products
Online Message
We will contact you within one business day. Please pay attention to your email.
Email: marcos.yuan@wangao.com.cn
Address: No. 688, Dinghai Road, Haimen City, Jiangsu Province
Mobile Version QR Code
WeChat Official Account
Copyright © 2025 Jiangsu Wangao Pharmaceutical Co., Ltd.